32
total announcements
THYROCARE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹7,497 Cr
P/E (TTM)
42.7
P/E (Forward)
29.6
EPS (TTM)
₹11.02
52W Low
₹342.55
52W High
₹662.00
Dividend Yield
1.98%
Beta
0.45
Price / Book
12.8
Debt / Equity
8.7
Revenue (TTM)
₹876 Cr
Gross Margin
54.96%
Operating Margin
26.99%
Thyrocare Technologies Limited
Thyrocare Technologies Limited has made available the audio recording of its earnings conference call held on July 23, 2026, for its unaudited financial results for the quarter ended June 30, 2026, on its website.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has announced that its Board of Directors has in-principle approved the evaluation of a proposed demerger of its wholly-owned subsidiary Nueclear Healthcare Limited's radiology business undertaking.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding re-appointment of M/s. Ernst & Young LLP as Internal Auditor of the Company for the Financial Year 2026-27.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a 24% year-on-year growth in consolidated revenue, driven by a 26% increase in the Pathology segment, and a 34% year-on-year growth in EBITDA and PAT.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has announced the outcome of its board meeting, which included the approval of unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review report. The board also approved the re-appointment of Ernst & Young LLP as the internal auditor for the financial year 2026-27.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Schedule of meet for analysts/investors to discuss the Company’s Unaudited Financial Results for the quarter ended June 30, 2026.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026, confirming that the regulation is not applicable to the company as all shares are in demat form and no rematerialisation requests were received during the quarter.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding Change in Auditors of the company, with M/s. M S K A & Associates LLP being replaced by M/s Price Waterhouse Chartered Accountants LLP as the Statutory Auditors.
Thyrocare Technologies Limited
Thyrocare Technologies Limited held its 26th Annual General Meeting on June 30, 2026, where 66 shareholders representing 61.10% of the total paid-up equity share capital attended. The meeting was conducted in physical mode at the Corporate Office of the Company, and remote e-voting was available from June 26 to June 29, 2026. The Independent Auditors' Reports on the Standalone and Consolidated Financial Statements did not contain any qualifications, reservations, or adverse remarks.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed for trading in Company’s equity shares for Designated Persons and their immediate relatives from July 01, 2026, and would be re-opened 48 hours after the announcement of un-audited financial results for the quarter ended June 30, 2026.